NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) announced financial results for Q2 2025, securing a $50 million partnership with Quazar Investment, receiving $2.5 million in NIH grants, and expanding technology through IP acquisitions. Clinical pipeline progress includes enrollment milestones for NEO100-01 and NEO212 therapies, with financial results showing increased expenses and a net loss. Executive Chairman highlights strategic initiatives and upcoming catalysts for accelerated growth.

NEO100-01, an intranasal therapy for malignant gliomas, expects full Phase 2a enrollment by September 2025 and top-line data readout in early 2026. NEO212, a bio-conjugated therapy for brain cancer, is on track to complete dosing for the final patient cohort in Phase I by 2025. NEO100-3, a pediatric indication trial, has initiated patient recruitment.

Financial results for Q2 2025 show G&A expenses of $984K and R&D expenses of $677K, leading to a net loss of $5.68M. Executive Chairman, Amir Heshmatpour, highlights transformative period for NeOnc, with upcoming catalysts including completion of enrollment for NEO100-01 Phase 2a and final cohort dosing for NEO212 Phase I in 2025, with FDA readouts expected by early 2026.

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a multi–Phase 2 clinical-stage biotechnology company developing novel therapies for brain cancer and CNS disorders. With a focus on transforming outcomes in oncology, the company has a strong IP portfolio, advanced delivery platforms, and collaborations with academic centers. Key trademarks include “NEO100” and “NEO212”.

Read more at GlobeNewswire: NeOnc Technologies Holdings Reports Second Quarter 2025